Findings of ICER Final Evidence Report for multiple myeloma therapies

12 May 2021
icer_big

US health technology assessor the Institute for Clinical and Economic Review (ICER) has released a Final Evidence Report assessing the comparative clinical effectiveness and value of three new treatments targeting the B-cell maturation antigen (BCMA) for heavily pre-treated patients with triple class refractory multiple myeloma (TCRMM) who have cycled through numerous previous lines of therapy:

  • idecabtagene vicleucel (“ide-cel,” Abecma, from Bristol-Myers Squibb ([YSE BMY) and bluebird bio [Nasdaq: BLUE]), a chimeric antigen receptor (CAR) T-cell therapy that the Food and Drug Administration] approved in March 2021 to treat TCRMM patients after four or more prior lines of therapy;
  • ciltacabtagene autoleucel (“cilta-cel,” from Johnson & Johnson [NYSE: JNJ} Janssen unit and Legend Biotech [Nasdaq: LEGN]), an investigational CAR T-cell therapy for which a rolling biologic license application (BLA) seeking approval for the treatment of adults with relapsed and refractory multiple myeloma was completed in the first quarter of 2021;
  • belantamab mafodotin-blmf (“belantamab,” Blenrep, from GlaxoSmithKline [LSE: GSK), which the FDA approved in August 2020 to treat TCRMM patients after four or more prior lines of therapy.

Downloads:  Final Evidence Report |  Report-at-a-Glance |  Policy Recommendations

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology